Published , updated
Their guidance aims to help clinicians manage patients who are currently on a medicine that requires monitoring during the COVID-19 pandemic.
The objective is to both protect patients from unnecessary health care visits and help preserve capacity in primary care.
Overall, they recommend that drug monitoring during the COVID-19 pandemic is prioritised for patients that will gain most benefit, i.e.:
- Those at risk of a serious adverse drug event that can be identified through monitoring
- People taking a Narrow Therapeutic Index drug during a phase when intensive monitoring is still required (e.g. upon initiation)
- Patients who have recently had an illness that may have impacted on how their drug works
Their advice is not intended as a definitive treatment strategy
They have provided advice on factors to consider when making monitoring decisions during COVID-19.
Our advice on individual medicines is below. We’ll also shortly be adding all our individual medicines advice as a word document for local adaptation.
The above pages are captured in the following word file and can be used for local adaptation